(KIDS) Orthopediatrics - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 471m USD | Total Return: -15.3% in 12m

Orthopedic Implants, Spinal Hardware, Medical Braces, Surgical Instruments
Total Rating 20
Safety 23
Buy Signal -0.96
Medical Devices
Industry Rotation: +5.3
Market Cap: 471M
Avg Turnover: 3.07M
Risk 3d forecast
Volatility45.7%
VaR 5th Pctl7.75%
VaR vs Median2.91%
Reward TTM
Sharpe Ratio-0.21
Rel. Str. IBD19.8
Rel. Str. Peer Group37
Character TTM
Beta1.134
Beta Downside1.371
Hurst Exponent0.458
Drawdowns 3y
Max DD69.12%
CAGR/Max DD-0.36
CAGR/Mean DD-0.55
EPS (Earnings per Share) EPS (Earnings per Share) of KIDS over the last years for every Quarter: "2021-03": -0.47, "2021-06": -0.19, "2021-09": -0.11, "2021-12": -0.24, "2022-03": -0.47, "2022-06": -0.02, "2022-09": -0.07, "2022-12": -0.35, "2023-03": -0.3, "2023-06": -0.13, "2023-09": -0.2, "2023-12": -0.29, "2024-03": -0.34, "2024-06": -0.26, "2024-09": -0.34, "2024-12": -0.29, "2025-03": -0.39, "2025-06": -0.11, "2025-09": -0.24, "2025-12": -0.26, "2026-03": -0.42,
Last SUE: 0.21
Qual. Beats: 0
Revenue Revenue of KIDS over the last years for every Quarter: 2021-03: 21.462, 2021-06: 26.695, 2021-09: 25.079, 2021-12: 24.813, 2022-03: 23.417, 2022-06: 32.928, 2022-09: 34.95, 2022-12: 30.994, 2023-03: 31.588, 2023-06: 39.559, 2023-09: 39.972, 2023-12: 37.613, 2024-03: 44.685, 2024-06: 52.802, 2024-09: 54.573, 2024-12: 52.667, 2025-03: 52.411, 2025-06: 61.082, 2025-09: 61.25, 2025-12: 61.605, 2026-03: 59.362,
Rev. CAGR: 25.20%
Rev. Trend: 98.7%
Last SUE: 0.77
Qual. Beats: 0

Warnings

Interest Coverage Ratio -4.2 is critical

Altman Z'' -1.51 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: KIDS Orthopediatrics

OrthoPediatrics Corp. (KIDS) is a medical device company specializing in the design and distribution of anatomically appropriate implants and instruments for pediatric orthopedic conditions. Headquartered in Warsaw, Indiana, the company maintains a product portfolio categorized into trauma and deformity correction, scoliosis and spinal procedures, and sports medicine.

The company operates within a niche medical sector where children were historically treated with modified adult implants; OrthoPediatrics addresses this by engineering hardware specifically for growing skeletons. Its business model relies on a direct sales force and independent distributors to reach pediatric surgeons and hospitals globally. Historical data on the companys valuation and growth metrics are available on ValueRay for further analysis.

Headlines to Watch Out For
  • Market share expansion within the underserved pediatric orthopedic surgical device segment
  • Revenue growth driven by international adoption of specialized trauma and deformity implants
  • Strategic acquisitions of pediatric bracing and sports medicine product lines
  • High research and development costs impacting short-term profitability and cash flow
  • Regulatory approval timelines for innovative scoliosis and spinal deformity correction systems
Piotroski VR-10 (Strict) 2.0
Net Income: -39.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.03 > 0.02 and ΔFCF/TA 5.33 > 1.0
NWC/Revenue: 81.66% < 20% (prev 91.58%; Δ -9.91% < -1%)
CFO/TA -0.01 > 3% & CFO -3.98m > Net Income -39.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.21 > 1.5 & < 3
Outstanding Shares: last quarter (23.7m) vs 12m ago 1.95% < -2%
Gross Margin: 73.07% > 18% (prev 0.73%; Δ 7.23k% > 0.5%)
Asset Turnover: 50.04% > 50% (prev 45.18%; Δ 4.86% > 0%)
Interest Coverage Ratio: -4.21 > 6 (EBITDA TTM -7.57m / Interest Expense TTM 6.97m)
Altman Z'' -1.51
A: 0.40 (Total Current Assets 245.9m - Total Current Liabilities 47.2m) / Total Assets 502.2m
B: -0.57 (Retained Earnings -285.9m / Total Assets 502.2m)
C: -0.06 (EBIT TTM -29.4m / Avg Total Assets 486.2m)
D: -1.76 (Book Value of Equity -287.3m / Total Liabilities 163.5m)
Altman-Z'' = -1.51 = D
Beneish M -2.90
DSRI: 1.08 (Receivables 54.4m/44.0m, Revenue 243.3m/212.5m)
GMI: 1.00 (GM 73.07% / 72.81%)
AQI: 1.05 (AQ_t 0.41 / AQ_t-1 0.39)
SGI: 1.15 (Revenue 243.3m / 212.5m)
TATA: -0.07 (NI -39.7m - CFO -3.98m) / TA 502.2m)
Beneish M = -2.90 (Cap -4..+1) = A
What is the price of KIDS shares?

As of May 28, 2026, the stock is trading at USD 17.90 with a total of 115,249 shares traded.
Over the past week, the price has changed by -1.32%, over one month by +13.15%, over three months by +0.62% and over the past year by -15.25%.

Is KIDS a buy, sell or hold?

Orthopediatrics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy KIDS.

  • StrongBuy: 3
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the KIDS price?
Analysts Target Price 24.7 37.8%
Orthopediatrics (KIDS) - Fundamental Data Overview as of 23 May 2026
Market Cap USD = 470.5m (470.5m USD * 1.0 USD.USD)
P/S = 1.934
P/B = 1.3964
Revenue TTM = 243.3m USD
EBIT TTM = -29.4m USD
EBITDA TTM = -7.57m USD
Long Term Debt = 100.4m USD (from longTermDebt, last quarter)
Short Term Debt = 2.93m USD (from shortTermDebt, last quarter)
Debt = 106.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 320k
Net Debt = 55.7m USD (calculated: Debt 106.6m - CCE 50.9m)
Enterprise Value = 526.3m USD (470.5m + Debt 106.6m - CCE 50.9m)
Interest Coverage Ratio = -4.21 (Ebit TTM -29.4m / Interest Expense TTM 6.97m)
EV/FCF = -41.69x (Enterprise Value 526.3m / FCF TTM -12.6m)
FCF Yield = -2.40% (FCF TTM -12.6m / Enterprise Value 526.3m)
FCF Margin = -5.19% (FCF TTM -12.6m / Revenue TTM 243.3m)
Net Margin = -16.31% (Net Income TTM -39.7m / Revenue TTM 243.3m)
Gross Margin = 73.07% ((Revenue TTM 243.3m - Cost of Revenue TTM 65.5m) / Revenue TTM)
Gross Margin QoQ = 73.09% (prev 73.22%)
Tobins Q-Ratio = 1.05 (Enterprise Value 526.3m / Total Assets 502.2m)
Interest Expense / Debt = 6.54% (Interest Expense 6.97m / Debt 106.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -23.2m (EBIT -29.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.21 (Total Current Assets 245.9m / Total Current Liabilities 47.2m)
Debt / Equity = 0.31 (Debt 106.6m / totalStockholderEquity, last quarter 338.7m)
 Debt / EBITDA = -7.36 (negative EBITDA) (Net Debt 55.7m / EBITDA -7.57m)
 Debt / FCF = -4.41 (negative FCF - burning cash) (Net Debt 55.7m / FCF TTM -12.6m)
 Total Stockholder Equity = 347.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.16% (Net Income -39.7m / Total Assets 502.2m)
RoE = -6.26% (Net Income TTM -39.7m / Total Stockholder Equity 633.4m)
RoCE = -4.00% (EBIT -29.4m / Capital Employed (Equity 633.4m + L.T.Debt 100.4m))
 RoIC = -5.07% (negative operating profit) (NOPAT -23.2m / Invested Capital 457.9m)
 WACC = 9.08% (E(470.5m)/V(577.1m) * Re(9.97%) + D(106.6m)/V(577.1m) * Rd(6.54%) * (1-Tc(0.21)))
Discount Rate = 9.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 1.78%
 [DCF] Fair Price = unknown (Cash Flow -12.6m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.21 | # QB: 0
Revenue Correlation: 98.68 | Revenue CAGR: 25.20% | SUE: 0.77 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.28 | Chg30d=+0.56% | Revisions=-14% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.17 | Chg30d=+5.56% | Revisions=-14% | Analysts=6
EPS current Year (2026-12-31): EPS=-1.05 | Chg30d=+1.55% | Revisions=+14% | GrowthEPS=-5.2% | GrowthRev=+12.2%
EPS next Year (2027-12-31): EPS=-0.68 | Chg30d=+2.16% | Revisions=+14% | GrowthEPS=+35.3% | GrowthRev=+11.9%
[Analyst] Revisions Ratio: -14%